Research programme: metabolic disorders therapy - BioFocus/Teijin

Drug Profile

Research programme: metabolic disorders therapy - BioFocus/Teijin

Latest Information Update: 15 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioFocus DPI; Teijin Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 31 Mar 2014 BioFocus has been acquired by Charles River Laboratories
  • 04 Feb 2003 No development reported - Preclinical for Metabolic disorders in United Kingdom (unspecified route)
  • 04 Jul 2001 Cambridge Drug Discovery has been acquired by BioFocus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top